Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06925542 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 14 to 16v9
  2. Study sites revised (14)v8
  3. Study sites revised (14)v7
  4. Study sites: 8 to 14v6
  5. Site details revised at 2 of 8 sitesv5
Show 3 earlier versionsHide 3 earlier versions
  1. Site details revised at 1 of 8 sitesv4
  2. Site details revised at 1 of 8 sitesv3
  3. Study sites: 7 to 8v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including active systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM).
Trial Details
NCT Number NCT06925542
Lead Sponsor CRISPR Therapeutics
Conditions
(from sponsor)		 SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis, Inflammatory Myopathy, Idiopathic, Myositis, Diffuse Cutaneous Systemic Sclerosis
Related terms Lupus Erythematosus, Systemic, Lupus Nephritis, Myositis, Scleroderma, Diffuse, Scleroderma, Systemic
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov